What ZYPREXA Injection contains
- The active substance is olanzapine. Each vial contains 10 mg of the active substance. - The other ingredients are lactose monohydrate, tartaric acid, hydrochloric acid and sodium hydroxide.
What ZYPREXA Injection looks like and contents of the pack
ZYPREXA comes as a yellow powder in a vial. A vial of ZYPREXA can provide you with 10 mg of olanzapine. Your doctor or nurse will make it up into a solution that will be given as an injection.
ZYPREXA Injection is available in a pack containing 1 or 10 vial(s). Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder: Eli Lilly Nederland BV, Grootslag 1 ? 5, NL-3991 RA, Houten, The Netherlands.
Manufacturer: Lilly Pharma Fertigung und Distribution GmbH & Co. KG, Teichweg 3, D-35396 Giessen, Germany.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
BelgiëBelgiqueBelgien Eli Lilly Benelux S.A.N.V. TélTel 32 02 548 84 84 .. - 359 2 491 41 40 eská republika Eli Lilly R, s.r.o. Tel 420 234 664 111 Danmark Eli Lilly Danmark AS Tlf 45 45 26 60 00 Deutschland Lilly Deutschland GmbH Tel 49 0 6172 273 2222 Eesti Eli Lilly Holdings Limited Eesti filiaal Tel 372 6817 280 a - .... 30 210 629 4600 España Lilly S.A. Tel 34 91 663 50 00 France Lilly France SAS Tél 33 0 1 55 49 34 34 Ireland Eli Lilly and Company Ireland Limited Tel 353 0 1 661 4377 Ísland Icepharma hf. LuxembourgLuxemburg Eli Lilly Benelux S.A.N.V. TélTel 32 02 548 84 84 Magyarország Lilly Hungária Kft. Tel 36 1 328 5100 Malta Charles de Giorgio Ltd. Tel 356 25600 500 Nederland Eli Lilly Nederland B.V. Tel 31 030 6025800 Norge Eli Lilly Norge A.S Tlf 47 22 88 18 00 Österreich Eli Lilly Ges. m.b.H. Tel 43 0 1 711 780 Polska Eli Lilly Polska Sp. z o.o. Tel 48 0 22 440 33 00 Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel 351 21 412 66 00 România Eli Lilly România S.R.L. Tel 40 21 4023000 Slovenija Eli Lilly farmacevtska druba, d.o.o. Tel 386 01 580 00 10 Slovenská republika Eli Lilly Slovakia, s.r.o.
Sími 354 540 8000 Tel 421 220 663 111
Italia Eli Lilly Italia S.p.A. Tel 39- 055 42571 Phadisco Ltd 357 22 715000 Latvija SuomiFinland Oy Eli Lilly Finland Ab PuhTel 358 09 8545 250 Sverige Eli Lilly Sweden AB Tel 46 08 7378800 United Kingdom Eli Lilly Holdings Limited, prstvniecba Latvij Eli Lilly and Company Limited Tel 371 67364000 Tel 44 0 1256 315000 Lietuva Eli Lilly Holdings Limited atstovyb Tel 370 5 2649600
This leaflet was last approved in {MM/YYYY}
--------------------------------------------------------------------------------------------------------------------------- (Perforation to allow health care provider information to be detached)
INSTRUCTIONS FOR HEALTH CARE PROFESSIONALS
Reconstitution and administration of ZYPREXA
Reconstitute ZYPREXA Powder for Solution for Injection only with water for injections.
ZYPREXA Powder for Solution for Injection must not be combined in the syringe with any commercially available medicinal products because of incompatibilities. See examples below.
Olanzapine for injection should not be combined in a syringe with haloperidol injection because the resulting low pH has been shown to degrade olanzapine over time.
Olanzapine for injection may not be combined in a syringe nor should it be used concomitantly with benzodiazepines.
Powder for Solution for Injection
Reconstitute ZYPREXA Powder for Solution for Injection using standard aseptic techniques for reconstitution of parenteral products.
1. Withdraw 2.1 ml of water for injections into a sterile syringe. Inject into a vial of ZYPREXA Powder for Solution for Injection.
2. Rotate the vial until the contents have completely dissolved, giving a yellow coloured solution. The vial contains 11.0 mg olanzapine as a solution of 5 mg/ml. If 2.0 ml solution is withdrawn, 1 mg olanzapine is retained in the vial and syringe, thus allowing delivery of 10mg olanzapine.
3. The following table provides injection volumes for delivering various doses of olanzapine:
Dose mg Volume of injection ml 10 2.0 7.5 1.5 5 1.0 2.5 0.5
4. Administer the solution intramuscularly. Do not administer intravenously or subcutaneously.
5. Discard the syringe and any unused solution in accordance with appropriate clinical procedures.
6. Use the solution immediately within 1 hour of reconstitution. Do not store above 25º C. Do not freeze.
Parenteral medicines should be inspected visually for particulate matter prior to administration.